Skip to content
BCI.INTEL
NLINKN1 Chip+PRIME.StudySYNCRStentrode+$200M.SeriesDPRECNLayer 7+FDA.BrkthruPARAMArgo+$20M.SeriesBBLKRKNeuroport+200.ImplantsEMTIVMN8+$45M.SeriesBKRNLFlux+Non-invasiveNRBLEHalo+Consumer.BCINEURONeuroPace+RNS.SystemCOGNICognixion+ALS.TrialFUND.YTD2026$2.8B.SectorTRIALSActive50+.ClinTrialsIMPLNTSHumans~100.Intracrtnl
endovascularbreakthroughinvestigational

Stentrode

Implant Type
endovascular
Electrodes
16
Channels
16
FDA Status
breakthrough
Clinical Stage
COMMAND Early Feasibility Study (6 patients); pivotal trial in preparation
Status
investigational
About

The Stentrode is the world's only endovascular brain-computer interface, implanted via a minimally invasive catheter procedure through the jugular vein into the superior sagittal sinus — a large blood vessel running along the top of the brain. No open brain surgery is required. The self-expanding nitinol stent embedded with thin-film platinum-iridium electrodes records local field potentials and high-gamma activity through the vessel wall. Signals are transmitted to a subcutaneous chest-mounted transmitter. Median deployment time is 20 minutes. The COMMAND study demonstrated 100% accurate deployment with zero neurologic safety events across 6 patients over 12 months. Patients have demonstrated control of mouse cursors, Apple Vision Pro, Amazon Alexa, and iPads.

Target Conditions
ALSmotor neuron diseaselocked-in syndromesevere paralysis
Milestones
2019-04First human implant in Melbourne, Australia
2020-08FDA Breakthrough Device Designation granted
2021-07SWITCH Australia feasibility study completed (4 patients)
2022-07First US patient implanted at Mount Sinai, New York
2023-01US patient sends Twitter post using thought alone
2024-06COMMAND early feasibility study initiated (6 patients)
2025-06COMMAND study: 100% deployment accuracy, zero neurologic safety events at 12 months
2025-11$200M Series D raised; total funding $345M
FDA Regulatory Pathway
Breakthrough Device Designation

FDA Breakthrough Device Designation provides more interactive communication with FDA during development and a priority review pathway. The device is still under investigation and not yet approved for commercial sale.

FDA Device Regulatory Guidance ↗